AU2003271510A1 - Formulation of oral compositions comprising arsenic trioxide and methods of use thereof - Google Patents

Formulation of oral compositions comprising arsenic trioxide and methods of use thereof

Info

Publication number
AU2003271510A1
AU2003271510A1 AU2003271510A AU2003271510A AU2003271510A1 AU 2003271510 A1 AU2003271510 A1 AU 2003271510A1 AU 2003271510 A AU2003271510 A AU 2003271510A AU 2003271510 A AU2003271510 A AU 2003271510A AU 2003271510 A1 AU2003271510 A1 AU 2003271510A1
Authority
AU
Australia
Prior art keywords
formulation
methods
oral compositions
arsenic trioxide
trioxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003271510A
Other languages
English (en)
Other versions
AU2003271510A8 (en
Inventor
Cyrus Rustam Kumana
Yoklam Kwong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Hong Kong HKU
Original Assignee
University of Hong Kong HKU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Hong Kong HKU filed Critical University of Hong Kong HKU
Publication of AU2003271510A1 publication Critical patent/AU2003271510A1/en
Publication of AU2003271510A8 publication Critical patent/AU2003271510A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2003271510A 2002-10-09 2003-10-08 Formulation of oral compositions comprising arsenic trioxide and methods of use thereof Abandoned AU2003271510A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41720002P 2002-10-09 2002-10-09
US60/417,200 2002-10-09
US48301403P 2003-06-25 2003-06-25
US60/483,014 2003-06-25
PCT/CN2003/000843 WO2004032822A2 (en) 2002-10-09 2003-10-08 Formulation of oral compositions comprising arsenic trioxide and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2003271510A1 true AU2003271510A1 (en) 2004-05-04
AU2003271510A8 AU2003271510A8 (en) 2004-05-04

Family

ID=32096185

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003271510A Abandoned AU2003271510A1 (en) 2002-10-09 2003-10-08 Formulation of oral compositions comprising arsenic trioxide and methods of use thereof

Country Status (6)

Country Link
US (1) US7521071B2 (enExample)
EP (2) EP3106169B1 (enExample)
JP (1) JP4786341B2 (enExample)
CN (1) CN103340899A (enExample)
AU (1) AU2003271510A1 (enExample)
WO (1) WO2004032822A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044559C (zh) * 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
US20080166425A1 (en) * 2002-10-09 2008-07-10 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US20080089949A1 (en) * 2006-10-13 2008-04-17 Yok-Lam Kwong Method for treating cancer using oral arsenic trioxide
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
US8906422B2 (en) * 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US20110008327A1 (en) * 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US8435959B2 (en) 2004-03-29 2013-05-07 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) * 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
WO2008046299A1 (en) * 2006-10-11 2008-04-24 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US8795738B2 (en) 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
CN103142648B (zh) * 2011-12-07 2015-04-15 浙江中医药大学 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂
ES2641847T3 (es) 2012-09-20 2017-11-14 Yogesh Narayan BENDALE Proceso para biosintetizar nanotrióxido de arsénico y su uso en el tratamiento de enfermedades que incluyen el cáncer
WO2014151317A1 (en) * 2013-03-15 2014-09-25 Rush University Medical Center Methods for treating cancer
SG11201706150QA (en) 2015-01-29 2017-08-30 Eupharma Pty Ltd Compositions containing arsenic and their use in methods of treatment
US10111836B2 (en) 2015-02-01 2018-10-30 Orsenix Holdings Bv High surface-area lyophilized compositions comprising arsenic for oral administration in patients
KR102015858B1 (ko) * 2015-10-23 2019-08-30 손영태 법제된 비상을 함유하는 면역력 증강을 위한 약학적 조성물
IL265986B (en) 2016-12-01 2022-09-01 Eupharma Pty Ltd Pharmaceutical composition comprising an alkali metal and/or an alkaline earth metal diarsenic (iii) tetraoxide and uses thereof
CN111184703B (zh) * 2018-11-15 2023-03-28 哈尔滨医大药业股份有限公司 三氧化二砷缓释小丸及其制备方法
US11583552B2 (en) 2021-02-17 2023-02-21 Manoj Maniar Pharmaceutical formulation of arsenic trioxide
EP4455672A1 (en) 2023-04-26 2024-10-30 Medsenic Method and kit for diagnosing and monitoring chronic graft-versus-host disease (cgvhd) using particular cytokine biomarkers
WO2025172482A1 (en) 2024-02-14 2025-08-21 Institut Gustave Roussy Oral composition of arsenic trioxide for cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
ES2395515T3 (es) * 1997-11-10 2013-02-13 Memorial Sloan Kettering Cancer Center Trióxido de arsénico para uso en el tratamiento de la leucemia
FR2786103A1 (fr) * 1998-10-30 2000-05-26 Assist Publ Hopitaux De Paris Utilisation de trioxyde d'arsenic pour la preparation d'un medicament destine a traiter les affections neoplastiques du tissu hematopoietique chez un mammifere et nouvelle composition pharmaceutique
CN1176665C (zh) * 2001-02-15 2004-11-24 暨南大学 治疗恶性淋巴瘤的药物及其配制方法
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof

Also Published As

Publication number Publication date
EP1562616A4 (en) 2008-12-17
EP3106169B1 (en) 2021-05-19
WO2004032822A3 (en) 2004-12-29
EP3106169A1 (en) 2016-12-21
US7521071B2 (en) 2009-04-21
JP2006503109A (ja) 2006-01-26
US20040126434A1 (en) 2004-07-01
JP4786341B2 (ja) 2011-10-05
EP1562616A2 (en) 2005-08-17
CN103340899A (zh) 2013-10-09
AU2003271510A8 (en) 2004-05-04
EP1562616B1 (en) 2016-06-01
WO2004032822A2 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
AU2003271510A1 (en) Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
EP1576150A3 (en) Methods and compositions for increasing the efficacy of biologically-active ingredients
AU2003259735A1 (en) Small-mer compositions and methods of use
AU2001268743A1 (en) Oral care compositions comprising chlorite and methods
AU2003237987A1 (en) Novel sweetener compositions and methods of use
AU2003267644A1 (en) Dental compositions and methods
AU2003277839A1 (en) Physical methods of dispersing characteristics use particles and compositions thereof
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
AU2002351356A1 (en) Stable oral compositions comprising casein phosphopeptide complexes and flouride
AU2003298583A1 (en) Chewing gum formulation and method of making the same
AU2003299441A1 (en) Nf-hev compositions and methods of use
AU2003239919A1 (en) Intravenous rifalazil formulation and methods of use thereof
AU2002367903A1 (en) Biologic-chemical herbicide compositions and methods of use
AU2002360556A1 (en) Stable oral compositions comprising casein phosphopeptide complexes and fluoride
AU2002952597A0 (en) Topical parasiticide formulations and methods of treatment
AU2002350079A1 (en) Gel composition and methods of use
AU2003239868A1 (en) Sunscreen compositions and methods of use thereof
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AU2003241103A1 (en) Compositions containing anti-hiv peptides and methods of use
AU2002252387A1 (en) Novel anti-inflammatory compositions and methods of use
AU2003206872A1 (en) Derivatives of (1-benzyl-piperidine-4-yl)-diphenyl-methanol and their use as pesticide
AU2003295713A1 (en) Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
AU2002355432A1 (en) Kavalactone compositions and methods of use
AU2003231017A1 (en) Emollient particles, sunscreen compositions and methods of manufacture thereof
AU2002340267A1 (en) Compositions and methods for reversal of drug resistance

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase